LDL-C-lowering therapies reduce major vascular events in patients aged ≥75 y

Area of Science:

• Cardiovascular Medicine
• Geriatrics
• Pharmacology

Background:

• High LDL cholesterol is a major risk factor for cardiovascular disease (CVD).
• Older adults are a growing population with significant CVD burden.
• Evidence on the benefits and risks of LDL cholesterol lowering in older adults is debated.

Purpose of the Study:

• To systematically review and meta-analyze randomized controlled trials (RCTs) evaluating the efficacy and safety of lowering LDL cholesterol in older patients.
• To provide evidence-based recommendations for lipid-lowering therapy in the elderly population.

Main Methods:

• Systematic review and meta-analysis of RCTs.
• Inclusion criteria: studies comparing LDL cholesterol-lowering therapy (primarily statins) versus placebo or no treatment in patients aged 65 years or older.
• Outcome measures: major adverse cardiovascular events (MACE), all-cause mortality, and adverse events.

Main Results:

• LDL cholesterol lowering significantly reduced MACE (e.g., myocardial infarction, stroke) in older adults.
• No significant increase in serious adverse events, including muscle-related adverse events and new-onset diabetes, was observed.
• The benefits of LDL cholesterol lowering were consistent across different age subgroups within the older population.

Conclusions:

• Lowering LDL cholesterol with statins is effective and safe for primary and secondary prevention of CVD in older adults.
• The findings support the use of statins in older individuals to reduce cardiovascular risk.
• Clinicians should consider statin therapy for eligible older patients based on established guidelines.